Refine
Document Type
- Article (2)
Language
- English (2)
Has Fulltext
- yes (2)
Is part of the Bibliography
- no (2)
Keywords
- Anobothrus konstantini Säring & Bick sp. nov. (1)
- Antarctic Peninsula (1)
- Filchner Trough (1)
- SEM (1)
- ecology (1)
- micro-CT analysis (1)
Institute
- Medizin (1)
Benthic samples were collected during two expeditions near the Antarctic Peninsula and in the South-Eastern Weddell Sea. During these studies, a new species of Ampharetidae Malmgren, 1867, Anobothrus konstantini Säring & Bick sp. nov., was found. Here we present a detailed description of this species. We used the traditional light microscope and scanning electron microscope (SEM) to identify and describe the diagnostic characters: a circular glandular band on segment 6; an elongate ridge between the notopodia on segment 12 and modified notochaetae on this segment; 16 thoracic, two intermediate and ten abdominal segments. For the first time, micro-computed tomography (micro-CT) was used for a species description of Anobothrus. Micro-CT provided information on the shape of the prostomium (Ampharete-type) and the arrangement of branchiae (four pairs in two rows, without a gap). In addition, we provide quantitative information on the environmental niche based on sediment parameters (chlorophyll a content, organic matter content, chloroplast equivalent, grain size) for the new Anobothrus species, relevant for, e.g., species distribution modelling. Finally, an identification key for all Anobothrus species is provided.
1. Objective: Chronic hepatitis C virus infections (HCV) cause a significant public health burden. Introduction of telaprevir (TVR) and boceprevir (BOC) has increased sustained virologic response rates (SVR) in genotype 1 patients but were accompanied by higher treatment costs and more side effects. Aim of the study was to assess outcomes and costs of treating HCV with TVR or BOC in routine care.
2. Material and Methods: Data was obtained from a non-interventional study. This analysis relates on a subset of 1,786 patients for whom resource utilisation was documented. Sociodemografic and clinical parameters as well as resource utilisation were collected using a web-based data recording system. Costs were calculated using official remuneration schemes.
3. Results: Mean age of patients was 49.2 years, 58.6% were male. In treatment-naive patients SVR-rates of 62.2% and 55.7% for TVR and BOC were observed (prior relapser: 68.5% for TVR and 63.5% for BOC; prior nonresponder: 45.6% for TVR and 39.1% for BOC). Treatment costs are dominated by costs for pharmaceuticals and range between €39,081 and €53,491. We calculated average costs per SVR of €81,347 (TVR) and €70,163 (BOC) in treatment-naive patients (prior relapser: 78,089 €/SVR for TVR and 82,077 €/SVR for BOC; prior non-responder: 116,509 €/SVR for TVR and 110,156 €/SVR for BOC). Quality of life data showed a considerable decrease during treatment.
4. Conclusion: Our study is one of few investigating both, outcomes and costs, of treating HCV in a real-life setting. Data can serve as a reference in the discussion of increasing costs in recently introduced agents
